Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Baxter International ( (BAX) ) is now available.
On June 11, 2025, Baxter International Inc. entered into an amended and restated five-year credit agreement, increasing its revolving credit facility to $2.2 billion and extending the maturity date. This agreement, which includes various lenders and JPMorgan Chase Bank as the administrative agent, allows Baxter and its Euro Borrowers to borrow in multiple currencies and replaces a previous €200 million facility. Additionally, Baxter amended a $645 million term loan agreement, extending its maturity and aligning its terms with the revolving credit facility. These financial arrangements aim to enhance Baxter’s liquidity and operational flexibility, potentially impacting its financial strategy and stakeholder interests.
The most recent analyst rating on (BAX) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Baxter International stock, see the BAX Stock Forecast page.
Spark’s Take on BAX Stock
According to Spark, TipRanks’ AI Analyst, BAX is a Neutral.
Baxter International’s overall stock score reflects a combination of mixed financial performance, neutral technical indicators, challenging valuation, and a positive earnings call. The significant factors influencing the score include operational challenges impacting profitability and the optimistic outlook from the earnings call, which suggests potential for future growth despite current difficulties.
To see Spark’s full report on BAX stock, click here.
More about Baxter International
Baxter International Inc. operates in the healthcare industry, focusing on providing a broad portfolio of essential medical products, including acute and chronic dialysis therapies, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, and surgical products. The company serves healthcare professionals and patients in more than 100 countries.
Average Trading Volume: 4,288,323
Technical Sentiment Signal: Strong Sell
Current Market Cap: $16.28B
For an in-depth examination of BAX stock, go to TipRanks’ Stock Analysis page.